Cover Image
市場調查報告書

全球醫療奈米技術市場:成長,趨勢,及預測(2017年∼2022年)

Global Healthcare Nanotechnology (Nanomedicine) Market - Segmented by Product Type, Application, Marker Type and Geography - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391463
出版日期 內容資訊 英文 106 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫療奈米技術市場:成長,趨勢,及預測(2017年∼2022年) Global Healthcare Nanotechnology (Nanomedicine) Market - Segmented by Product Type, Application, Marker Type and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 106 Pages
簡介

高精度可靠性高的醫療奈米技術,今後是值得期待成長的領域之一。2013年臨床腫瘤獨佔市場,不過,在調查期間中心血管領域的奈米醫療急速成長。

本報告提供全球醫療奈米技術市場相關調查,市場概要,各應用領域、疾病、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會、課題分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 基本單位
  • 基本貨幣
  • 調查對象期間及預測
  • 一般調查的前提條件
  • 報告的說明

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 研究資金的增加
    • 心血管疾病的盛行率的上升
    • 老年人口的增加
    • 奈米醫療的興趣
    • 龐大的未滿足需求
    • 新加入企業的增加競爭激烈化
  • 市場阻礙因素
    • 奈米醫療為基礎的醫療設備的成本
    • 核准流程的長度
  • 市場機會
    • 癌症治療的應用擴大
  • 主要課題
    • 毒性

第7章 全球醫療奈米技術市場:市場區隔

  • 各應用領域
    • 藥物輸送
    • 醫藥品
    • 生物材料
    • 活性植入
    • 體外診斷
    • 體內成像
  • 各疾病
    • 神經系統疾病
    • 心血管疾病
    • 腫瘤
    • 發炎
    • 感染疾病
    • 其他

第8章 全球醫療奈米技術市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 中南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Abbott Laboratories
  • CombiMatrix Corporation
  • GE Healthcare
  • Sigma-Tau Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Mallinckrodt PLC
  • Merck & Company, Inc.
  • Nanosphere, Inc.
  • Pfizer, Inc.
  • Celgene Corporation
  • Teva Pharmaceutical Industries Ltd.
  • UCB (Union chimique belge) SA
  • 其他的企業

第11章 分析師的投資機會預測

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 33511

The global healthcare nanotechnology market was valued at USD 156.56 billion in 2017. This market is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2017. North America dominates the market, and is expected to maintain its position over the forecast period.

Rising applications in Oncology

Nanomedicine is a promising mode of cancer treatment and has several applications in oncology. Cancer has a major impact on United States and across the world. As per WHO, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million were the cancer-related deaths. Therefore the demand for nanomedicine in the market was in order to curb such high incidence rate and is expected to boost market. Researchers have been working on improvisation of techniques, to deliver chemotherapeutic agents precisely at the Nano level in tumorous tissues. Nanoscale objects are used by themselves or as parts of larger devices containing multiple nanoscale objects and due their small size, nanoscale devices can readily interact with the biomolecules on both the surface and the inner cells and they have the potential to diagnose and treat cancer. Nanoparticles are majorly been used as nanocarriers, to deliver the cytotoxic drugs to the tumor cells and tissues. The increasing incidence of cancer and importance of nanomedicine in modern cancer treatment procedures, are expected to drive the nanomedicines demand during the forecast period.

Huge costs of the medical devices

Cost is the main factor that is often overlooked, which is specifically important in the face of ever increasing healthcare cost and unpredictable reimbursement environment. Nanomedicines are no different; there are several FDA approved nanoparticle-based products in the market, which can be compared with their non-nanoparticle based counterparts. Although these formulations may be more efficient and less toxic than their counterparts, their costs may also be significantly high. The average cost per dose of anticancer drug doxorubicin is about USD 62-162, compared to USD 5,594 for Doxil, which is a nanoparticle containing doxorubicin. Similarly, the average cost per dose of anticancer drug Abraxane, a paclitaxel nanoformulation, is USD 5,054. Therefore, owing to the inability of the industry to find a cost-effective method of scaling up the production, the cost of nanomedicine therapies is likely to remain high over the forecast period. This high cost of nanoparticle-assisted medicine, relative to its traditional counterparts, is hindering the growth of the market.

US Healthcare Nanotechnology Market

The US-based pharmaceutical companies believe that nanomedicines is the next big thing, as it has been opening up newer and has more accurate options for the target drug delivery, and resulting in very few side effects. The Swiss Group's Kadcyla received the approval of the United States in February 2017. The product treats breast cancer with very less side-effects. In addition with the booming R&D, United States has also initiated several measures in the recent times, to advance and develop the nanotechnology applications in healthcare. Owing to the large geriatric population, increasing need for diagnostics, growing need of augmented cancer therapies, government initiatives, and increasing awareness of nanomedicines, the US healthcare nanotechnology sector will witness substantial growth during the forecast period.

The key players in the market are ABBOTT LABORATORIES, COMBIMATRIX CORPORATION, GE HEALTHCARE, SIGMA-TAU PHARMACEUTICALS Inc., JOHNSON & JOHNSON, MALLINCKRODT Plc, MERCK & COMPANY, Inc., NANOSPHERE, Inc., PFIZER, and CELGENE CORPORATION.

Reasons to Purchase this Report

Current and future healthcare nanotechnology market outlook in the developed and emerging markets

Analyzing various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. INTRODUCTION

  • 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

  • 5.1 CURRENT MARKET SCENARIO
  • 5.2 PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF CONSUMERS
    • 5.2.3 THREATS OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
    • 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 MARKET DRIVERS
    • 6.1.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES
    • 6.1.2 INCREASING RESEARCH FUNDING
    • 6.1.3 RISING AWARENESS OF NANOMEDICINE APPLICATION
    • 6.1.4 RISING GERIATRIC POPULATION
  • 6.2 MARKET RESTRAINTS
    • 6.2.1 HIGH COSTS OF NANOTECHNOLOGY-BASED MEDICAL DEVICES
    • 6.2.2 TIME-CONSUMING PRODUCT APPROVAL
  • 6.3 OPPORTUNITIES
  • 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

  • 7.1 SEGMENTATION-BY APPLICATIONS
    • 7.1.1 DRUG DELIVERY
    • 7.1.2 DRUGS
    • 7.1.3 BIOMATERIALS
    • 7.1.4 ACTIVE IMPLANTS
    • 7.1.5 IN-VITRO DIAGNOSTIC
    • 7.1.6 IN-VIVO IMAGING
  • 7.2 BY DISEASE
    • 7.2.1 NEUROLOGICAL DISEASES
    • 7.2.2 CARDIOVASCUAR DISEASES
    • 7.2.3 ONCOLOGY
    • 7.2.4 DISPOSABLE IVD DEVICES
    • 7.2.5 ANTI-INFLAMMATORY
    • 7.2.6 ANTI-INFECTIVE
    • 7.2.7 OTHERS
  • 7.3 SEGMENTATION-BY GEOGRAPHY
    • 7.3.1 NORTH AMERICA
      • 7.3.1.1 UNITED STATES
      • 7.3.1.2 CANADA
      • 7.3.1.3 MEXICO
    • 7.3.2 EUROPE
      • 7.3.2.1 FRANCE
      • 7.3.2.2 GERMANY
      • 7.3.2.3 UNITED KINGDOM
      • 7.3.2.4 ITALY
      • 7.3.2.5 SPAIN
      • 7.3.2.6 REST OF EUROPE
    • 7.3.3 ASIA-PACIFIC
      • 7.3.3.1 CHINA
      • 7.3.3.2 JAPAN
      • 7.3.3.3 INDIA
      • 7.3.3.4 AUSTRALIA & NEW ZEALAND
      • 7.3.3.5 SOUTH KOREA
      • 7.3.3.6 REST OF ASIA-PACIFIC
    • 7.3.4 MIDDLE EAST & AFRICA
      • 7.3.4.1 GCC
      • 7.3.4.2 SOUTH AFRICA
      • 7.3.4.3 REST OF THE MIDDLE EAST & AFRICA
    • 7.3.5 SOUTH AMERICA
      • 7.3.5.1 BRAZIL
      • 7.3.5.2 ARGENTINA
      • 7.3.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

  • 8.1 MERGERS & ACQUISITION ANALYSIS
  • 8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  • 8.3 NEW PRODUCTS LAUNCHES

9. KEY PLAYERS

  • 9.1 ABBOTT LABORATORIES
  • 9.2 COMBIMATRIX CORPORATION
  • 9.3 GE HEALTHCARE
  • 9.4 SIGMA-TAU PHARMACEUTICALS, INC.
  • 9.5 JOHNSON & JOHNSON
  • 9.6 MALLINCKRODT PLC
  • 9.7 MERCK & COMPANY, INC.
  • 9.8 NANOSPHERE, INC.
  • 9.9 PFIZER, INC.
  • 9.10 CELGENE CORPORATION
  • 9.11 OTHERS

10. FUTURE OF THE MARKET

Back to Top